Baloxavir Marboxil

  • TRADE NAME: Xofluza (Shionogi)
  • INDICATIONS: Indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
  • CLASS: Polymerase acidic (PA) endonuclease inhibitor
  • HALF-LIFE: 79.1 hours

FDA APPROVAL DATE: 10/24/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Calcium Hydroxylapatite, Selenium, Zinc

PREGNANCY CATEGORY: N/A
no available data

Our database has 8 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
RESPIRATORY.
OTHER.


Page last updated 08/20/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top